rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Inogen, Inc

INGN · Nasdaq

Health CareMedical DevicesAbove a falling average

INGN stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 50 weeks. It is 6.9% above that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 50
Industry in uptrend
29% -4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$285K
Officials’ trades on record
1
Institutions holding
123 (+7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

22 Apr – 21 Oct
15%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$135K$0$115KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Lamar Smith House: U.S. House ClerkTX21bought$1k–$15k20 Nov 2018filed 13 Dec 2018

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 1
WhoDidSharesTraded
Boyer Jennifer M. YiEVP Entrprs Enblmnt, Ch HR Offsold10,938at $6.601 Jul 2026filed 6 Jul 2026
Boyer Jennifer M. YiEVP Entrprs Enblmnt, Ch HR Offsold10,770at $6.5329 May 2026filed 2 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders123+7 on the quarter
New · exited20 · 13
Reported value$114.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20261,748,986$11.3M+101,902+6.2%
ARMISTICE CAPITAL, LLCreduced · filed 14 Aug 20261,096,000$7.1M-104,000−8.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,038,316$6.7M+1,611+0.2%
AMERIPRISE FINANCIAL INCadded · filed 14 Aug 2026983,028$6.3M+123,485+14.4%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026937,334$6.0M+510,216+119.5%
DAFNA Capital Management LLCunchanged · filed 14 Aug 2026845,179$5.5M00.0%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPadded · filed 13 Aug 2026743,252$4.8M+157,093+26.8%
MORGAN STANLEYadded · filed 13 Aug 2026646,276$4.2M+105,111+19.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026641,521$4.1M+27,992+4.6%
STATE STREET CORPadded · filed 7 Aug 2026591,943$3.8M+18,739+3.3%
31 Mar 2023 – 30 Jun 2026
110118125Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Kevin P. Smith Company insiderEVP, Bus Dev, GC & Sec · last 1 Sep 20260 · 0
Kevin Raymond Merrill Smith Company insiderCEO and President · last 1 Sep 20261 · 0
Mary E. Wright Company insiderVP, Chief Accounting Officer · last 1 Sep 20260 · 0
Andrew P. Reding Company insiderEVP, COO · last 6 Jul 20260 · 0
Boyer Jennifer M. Yi Company insiderEVP Entrprs Enblmnt, Ch HR Off · last 1 Jul 20260 · 2
Elizabeth Mora Company insiderDirector · last 5 Jun 20260 · 0
Glenn S. Boehnlein Company insiderDirector · last 5 Jun 20260 · 0
Heather D. Rider Company insiderDirector · last 5 Jun 20261 · 3
Kevin M. King Company insiderDirector · last 5 Jun 20260 · 0
Mary Kay Ladone Company insiderDirector · last 5 Jun 20260 · 0
Mira Kirti Sahney Company insiderDirector · last 5 Jun 20260 · 0
Vafa Jamali Company insiderDirector · last 5 Jun 20260 · 0

Same industry

RCEL Avita MedicalLeading+127%
HTFL HeartflowLeading+59%
ATRC AtriCureLeading+51%
HAE HaemoneticsLeading+44%
BVS BioventusLeading+24%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202544.2%
Operating profit marginFY 2025 · to 31 Dec 2025-8.7%
Free cash flow marginFY 2025 · to 31 Dec 2025-3.9%
Return on capital employedFY 2025 · to 31 Dec 2025-12.8%
Research spendFY 2025 · to 31 Dec 20255.6%
Share count trendFY 2025 · to 20 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$103.7M
Free cash flowFY 2025 · to 31 Dec 2025−$13.7M

Analyst forecasts

No analyst forecasts yet.